NEWARK, Calif., June 7, 2021 /PRNewswire/ -- Protagonist
Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company")
today announced that management will host an investor
conference call and webcast to provide a brief corporate update and
discuss data from its ongoing Phase 2 clinical study evaluating
rusfertide in polycythemia vera (PV), which was selected as an oral
presentation at the European Hematology Association 2021 Annual
Congress. The conference call will take place on Friday, June 11, 2021, at 8:00 a.m. EDT (14:00
The call will feature members of the Protagonist management team
and Ronald Hoffman, M.D., Albert A.
and Vera G. List Professor of Medicine, Hematology and Medical
Oncology, and Director of the Myeloproliferative Disorders Research
Program at Mount Sinai Hospital, and a lead investigator of the
Phase 2 study.
Rusfertide (PTG-300) Eliminates the Need for Therapeutic
Phlebotomy in Both Low and High-Risk Polycythemia Vera (PV)
Patients (S200; Kremyanskaya, et al). The oral presentation
will be made available on demand to registered meeting attendees at
ehaweb.org on Friday, June 11, 2021
at 9:00 CEST.
Conference Call and Webcast Information
Live audio of the conference call will be simultaneously
broadcast over the internet. The call will be available to
investors, members of the news media, and the general public.
To access the live call, dial (877) 870-4263 (U.S./Canada) or (412) 317-0790 (international) five
minutes prior to the call and ask to be joined to the Protagonist
Therapeutics call. A live and archived webcast will be accessible
in the Investors section of the Company's website at
About Protagonist Therapeutics
Protagonist Therapeutics is a biopharmaceutical company
with multiple peptide-based investigational new chemical entities
in different stages of development, all derived from the Company's
proprietary technology platform.
Protagonist's pipeline includes rusfertide (PTG-300), an
investigational, injectable hepcidin mimetic currently in a Phase 2
proof-of-concept clinical trial for polycythemia vera (PV), a Phase
2 study in PV subjects with high hematocrit levels, and a Phase 2
study for hereditary hemochromatosis. Based on the feedback
provided by the FDA and EU regulatory authorities, the Company
plans to initiate a single, global Phase 3 randomized,
placebo-controlled trial evaluating the efficacy and safety of a
once weekly, subcutaneously self-administered dose of rusfertide.
The Company is also developing PN-943, an investigational, orally
delivered, gut-restricted alpha-4-beta-7 integrin specific
antagonist peptide currently in a Phase 2 study for the potential
treatment of inflammatory bowel disease, with ulcerative colitis as
the initial targeted indication.
The Company has a worldwide license and collaboration agreement
with Janssen Biotech, Inc., for the development of oral peptide
IL-23 receptor antagonists. Compounds included in this agreement
are PTG-200, PN-235 and PN-232. PTG-200 is an orally delivered,
gut-restricted, interleukin-23 receptor specific antagonist peptide
in a Phase 2 clinical trial for Crohn's disease. PN-235 and PN-232,
both second-generation oral interleukin-23 receptor antagonist
candidates, are currently in Phase 1 studies.
Protagonist is headquartered in Newark, California.
For further information, please
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include
statements regarding our intentions or current expectations
concerning, among other things, among other things, our plans to
present updated rusfertide data at EHA and conduct a Phase 3 trial
evaluating rusfertide for PV. In some cases, you can identify these
statements by forward-looking words such as "anticipate,"
"believe," "may," "will," "expect," or the negative or plural of
these words or similar expressions. Forward-looking statements are
not guarantees of future performance and are subject to risks and
uncertainties that could cause actual results and events to differ
materially from those anticipated, including, but not limited to,
our ability to develop and commercialize our product candidates,
our ability to earn milestone payments under our collaboration
agreements, the impact of the current COVID-19 pandemic on our
discovery and development efforts, our ability to use and expand
our programs to build a pipeline of product candidates, our ability
to obtain and maintain regulatory approval of our product
candidates, our ability to operate in a competitive industry and
compete successfully against competitors that have greater
resources than we do, and our ability to obtain and adequately
protect intellectual property rights for our product
candidates. Additional information concerning these and other
risk factors affecting our business can be found in our periodic
filings with the Securities and Exchange Commission, including
under the heading "Risk Factors" contained in our most recently
filed periodic reports on Form 10-K and Form 10-Q filed with
the Securities and Exchange Commission. Forward-looking
statements are not guarantees of future performance, and our actual
results of operations, financial condition and liquidity, and the
development of the industry in which we operate, may differ
materially from the forward-looking statements contained in this
press release. Any forward-looking statements that we make in
this press release speak only as of the date of this press release.
We assume no obligation to update our forward-looking statements,
whether as a result of new information, future events or otherwise,
after the date of this press release.
View original content to download
SOURCE Protagonist Therapeutics, Inc.